Authored By: Sarah
11 Jul 2024

 Zika Virus Therapeutics Market Size to grow by USD 4174.3 million between 2024-2028

According to a research report “ Zika Virus Therapeutics Market” by Product (Acetaminophen, Other NSAIDs) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 4174.3 million, at a CAGR of  4.5% during the forecast period. The Zika virus therapeutics market has experienced a significant development with InBios International Inc.'s approval of the ZIKV Detect 2.0 IgM Capture enzyme-linked immunosorbent assay (ELISA) for the diagnostic identification of Zika virus immunoglobulin M (IgM) antibodies in human serum. This test, which is widely utilized for Zika diagnostic procedures, is marketed in the US and has been granted emergency use authorization (EUA) by the US Food and Drug Administration (FDA). The ZIKV Detect 2.0 IgM Capture ELISA is designed to detect the presence of IgM antibodies, which are naturally produced by the immune system in response to Zika virus infection. This approval represents a crucial advancement in the diagnostic tools available for detecting and managing Zika virus outbreaks.

Browse market data tables, figures, and in-depth TOC on “Zika Virus Therapeutics Market” by Product (Acetaminophen, Other NSAIDs) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Product, the Acetaminophen segment is projected to dominate the market size in 2024

ai_market_segmentation_by

By Geography, North America  segment is expected to hold the largest market size for the year 2024

The Zika Virus Therapeutics Market represents a significant business opportunity for pharmaceutical companies, as the demand for effective treatments and vaccines continues to rise. With the World Health Organization declaring Zika a public health emergency in 2016, the market is poised for substantial growth. Key players are investing heavily in research and development to bring innovative solutions to market, focusing on antivirals, vaccines, and diagnostic tools. The market is expected to experience robust expansion in the coming years, driven by increasing global prevalence and the need for effective interventions.

North America is forecasted to hold the largest market size by region in 2024

The Zika Virus Therapeutics Market represents a significant business opportunity for pharmaceutical companies, as the demand for effective treatments and vaccines continues to rise. With the World Health Organization declaring Zika a public health emergency in 2016, investments in research and development for Zika virus therapeutics have surged. Market growth is driven by the increasing prevalence of Zika infections, particularly in tropical regions, and the need for effective interventions to mitigate the health and economic impact of the virus. Companies are focusing on developing antiviral drugs, vaccines, and diagnostic tools to address this unmet medical need.

The Zika Virus Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Aurobindo Pharma Ltd.
  • Bharat Biotech Ltd.
  • BioVaxys Technology Corp.
  • Emergent BioSolutions Inc.
  • GeoVax Labs Inc.
  • Granules India Ltd.
  • Inovio Pharmaceuticals Inc.
  • Johnson and Johnson Services Inc.
  • Merck and Co. Inc.
  • Moderna Inc.
  • Perrigo Co. Plc
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Valneva SE
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Zika virus outbreak, marked by clinical manifestations such as fever, rash, arthralgia, and headache, has been declared a global health emergency by the World Health Organization. The epidemic, primarily spread through Aedes mosquitoes, can also be transmitted through sexual contact. Zika virus infection poses a significant risk to foetuses, leading to severe birth defects like microcephaly. Several potential treatments are under investigation, including small molecule inhibitors. Acetaminophen is currently used to alleviate symptoms like fever and headache. Diagnostic companies like Quest Diagnostics, DiaSorin, TIB Molbiol Group, and Roche are developing tests for Zika virus detection. However, there is currently no specific antiviral treatment or vaccine available. Co-infections with diseases like pneumonia, typhoid, malaria, and dengue can complicate diagnosis and treatment. Nature Biomedical Engineering recently reported on potential treatments for Zika virus, including antiviral drugs and gene therapy. The Zika virus therapeutics market is expected to grow significantly due to the ongoing epidemic and the need for effective treatments.

Market Research Overview

The Zika virus therapeutic market has gained significant attention due to the epidemic proportions of the disease, particularly in relation to congenital disabilities such as microcephaly and optic neuropathy. Clinical manifestations of Zika virus infection include pruritic maculopapular rashes, arthralgia, headache, malaise, fever, and conjunctivitis. Comorbidities like pneumonia, typhoid, malaria, and dengue can complicate diagnosis and treatment. The Zika virus is transmitted primarily by the Aedes mosquito, and diagnostic testing is crucial for early detection and intervention. Companies such as Mylab, Siemens Healthcare GmbH, Quest Diagnostics, DiaSorin, TIB Molbiol Group, and Roche offer RT-PCR test kits for Zika virus detection. Treatment strategies for Zika virus infection focus on symptomatic relief, supportive care, and antiviral medications. Acetaminophen is commonly used for fever and pain relief. Preclinical studies are exploring novel drug targets, treatment modalities, and therapeutic approaches. Vaccines and repurposed existing drugs are potential treatment options, with Emricasan, a small molecule inhibitor of caspase-8, showing antiviral activity against Zika virus in laboratory studies. The market for Zika virus therapeutics is segmented into clinic, homecare, and hospital settings. Effective drug targets and optimal dosing regimens are under investigation, with safety and efficacy being key considerations in the drug development process. Reimbursement policies and commercial opportunities are driving factors in the market, with ethical considerations and patient recruitment difficulties presenting challenges. The Zika virus outbreaks have highlighted the need for advances in technology, genomic analysis, and computational modeling to better understand the virus's pathogenesis, transmission dynamics, and gaps in understanding. Follow-up care and diagnostic testing are essential for managing the long-term effects of Zika virus infection, particularly in relation to neurological complications and severe cases. The therapeutic market for Zika virus infection is expected to grow significantly in the coming years, driven by the need for effective treatments and vaccines, as well as the ongoing public health concerns related to the virus's transmission through sexual contact and mother-to-fetus transmission. The market is also influenced by the development of drug-resistant strains and host factors that impact viral replication.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio